Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26:1–158.

Article  PubMed  Google Scholar 

Kenet G, Chen YC, Lowe G, Percy C, Tran H, von Drygalski A, et al. Real-world rates of bleeding, factor VIII use, and quality of life in individuals with severe haemophilia A receiving prophylaxis in a prospective, noninterventional study. J Clin Med. 2021;10:5959.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021;137:2231–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379:811–22.

Article  CAS  PubMed  Google Scholar 

Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9:418–35.

Article  CAS  PubMed  Google Scholar 

Martensson A, Letelier A, Hallden C, Ljung R. Mutation analysis of Swedish haemophilia B families - high frequency of unique mutations. Haemophilia. 2016;22:440–5.

Article  CAS  PubMed  Google Scholar 

Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia. 2012;18:276–83.

Article  CAS  PubMed  Google Scholar 

Brown K, Green G. The haemophilia drug market. Nat Rev Drug Discov. 2018;17:541–2.

Article  CAS  PubMed  Google Scholar 

Camire RM. Bioengineering factor Xa to treat bleeding. Thromb Res. 2016;141:S31–3.

Article  CAS  PubMed  Google Scholar 

George LA, Thalji NK, Raffini LJ, Gimotty PA, Camire RM. Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L). J Thromb Haemost. 2015;13:1694–8.

Article  CAS  PubMed  Google Scholar 

Ivanciu L, Camire RM. Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity. Blood. 2015;126:94–102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thalji NK, Camire RM. Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. Curr Opin Hematol. 2017;24:453–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parsons-Rich D, Hua F, Li G, Kantaridis C, Pittman DD, Arkin S. Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa(I16L)). J Thromb Haemost. 2017;15:931–7.

Article  CAS  PubMed  Google Scholar 

Sun J, Hakobyan N, Valentino LA, Feldman BL, Samulski RJ, Monahan PE. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood. 2008;112:4532–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun J, Hua B, Livingston EW, Taves S, Johansen PB, Hoffman M, et al. Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis. Blood. 2017;129:2161–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hakobyan N, Enockson C, Cole AA, Sumner DR, Valentino LA. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia. 2008;14:804–9.

Article  CAS  PubMed  Google Scholar 

Sang Y, Roest M, de Laat B, de Groot PG, Huskens D. Interplay between platelets and coagulation. Blood Rev. 2021;46:100733.

Article  CAS  PubMed  Google Scholar 

Yang L, Jiang J, Drouin LM, Agbandje-McKenna M, Chen C, Qiao C, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci USA. 2009;106:3946–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang L, Li J, Xiao X. Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol. 2011;709:127–39.

Article  CAS  PubMed  Google Scholar 

Xue F, Li H, Wu X, Liu W, Zhang F, Tang D, et al. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial. Lancet Haematol. 2022;9:e504–e13.

Article  CAS  PubMed  Google Scholar 

Swearingen CA, Chambers MG, Lin C, Marimuthu J, Rito CJ, Carter QL, et al. A short-term pharmacodynamic model for monitoring aggrecanase activity: injection of monosodium iodoacetate (MIA) in rats and assessment of aggrecan neoepitope release in synovial fluid using novel ELISAs. Osteoarthritis Cartilage. 2010;18:1159–66.

Article  CAS  PubMed  Google Scholar 

Yu P, Venkat P, Chopp M, Zacharek A, Shen Y, Liang L, et al. Deficiency of tPA exacerbates white matter damage, neuroinflammation, glymphatic dysfunction and cognitive dysfunction in aging mice. Aging Dis. 2019;10:770–83.

Article  PubMed  PubMed Central  Google Scholar 

Kung SH, Hagstrom JN, Cass D, Tai SJ, Lin HF, Stafford DW, et al. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood. 1998;91:784–90.

Article  CAS  PubMed  Google Scholar 

Schuettrumpf J, Herzog RW, Schlachterman A, Kaufhold A, Stafford DW, Arruda VR. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood. 2005;105:2316–23.

Article  CAS  PubMed  Google Scholar 

Broze GJ Jr, Yin ZF, Lasky N. A tail vein bleeding time model and delayed bleeding in hemophiliac mice. Thromb Haemost. 2001;85:747–8.

Article  CAS  PubMed  Google Scholar 

Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001;413:74–8.

Article  CAS  PubMed  Google Scholar 

He P, Zhang F, Zhong C, Li M, Zheng J, Hua B, et al. Timely and large dose of clotting factor IX provides better joint wound healing after hemarthrosis in hemophilia B mice. Int J Hematol. 2019;110:59–68.

Article  PubMed  Google Scholar 

Zhang F, Xu M, Yang Q, Hua B, Xia B, Lin Z, et al. A translational study of TNF-alpha antagonists as an adjunctive therapy for preventing hemophilic arthropathy. J Clin Med. 2019;9:75.

Article  PubMed  PubMed Central  Google Scholar 

Valentino LA, Hakobyan N. Histological changes in murine haemophilic synovitis: a quantitative grading system to assess blood-induced synovitis. Haemophilia. 2006;12:654–62.

Article  CAS  PubMed  Google Scholar 

Zhang F, Yan X, Li M, Hua B, Xiao X, Monahan PE, et al. Exploring the potential feasibility of intra-articular adeno-associated virus-mediated gene therapy for hemophilia arthropathy. Hum Gene Ther. 2020;31:448–58.